Title page
Word count: 2754

Title: COVID-19 Has Long Term Effects on Chemosensory Functions

Authors: Nicholas **Bussiere**[1]; Jie **Mei**[1], PhD; Cindy **Levesque-Boissonneault**[1], MSc; Mathieu **Blais**[2,3], PhD; Sara **Carazo**[4], MD, PhD; Francois **Gros-Louis**[2,3], PhD; Gaston **De Serres**[4], MD, PhD; Nicolas **Dupré**[5,6], MD, MSc, FRCP FAAN; Johannes **Frasnelli**[1], MD

[1] Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

[2] Axe Médecine régénératrice, CHU de Québec–Université Laval, Québec City, QC, Canada

[3] Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada

[4] Institut National de Santé Publique du Québec, Québec City, QC, Canada

[5] Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada

[6] Axe Neurosciences, CHU de Québec–Université Laval, Québec City, QC, Canada

Corresponding Author :

Johannes Frasnelli MD,

Université du Québec à Trois-Rivières,

3351, boul. des Forges, C.P. 500,

Trois-Rivières, QC G9A 5H7 Canada

Email: johannes.a.frasnelli@uqtr.ca

Abstract:

Importance: A number of studies have revealed either self-reported chemosensory alterations in large groups or objective quantified chemosensory impairments in smaller populations of patients diagnosed with COVID-19. However, due to the great variability in published results regarding COVID-19-induced chemosensory impairments and their follow-up, prognosis for chemosensory functions in patients with such complaints remains unclear.

Objective: To describe the various chemosensory alterations associated with COVID-19 and their prevalence and evolution at 3 to 7 months after infection.

Design, Setting, and Participants: A follow-up study of 704 health care workers with a RT-PCR confirmed SARS-CoV-2 infection between 28/2/2020 and 14/6/2020 was conducted 3 to 7 months after onset of symptoms. Data were collected with an online questionnaire. Participant had to be ≥18 years old without respiratory illness in the 2 weeks prior to questionnaire completion.

Main outcomes and measures: Outcomes included differences in reported chemosensory self-assessment of olfactory, gustatory, and trigeminal functions across time points and Chemosensory Perception Test scores from an easy-to-use at-home self-administered chemosensory test.

Results:

Among the 704 health care worker participants, 593 (84.2%) were women, the mean (SD) age was 42 (12) years and the questionnaire was answered on average 4.8 (0.8) months after COVID-19. During COVID-19, a decrease in olfactory, gustatory, and trigeminal sensitivities were reported by 81.3%, 81.5% and 48.0% respectively. Three to seven months later, reduced

sensitivity was still reported by 52.0%, 41.9% and 23.3% respectively. Chemosensory Perception Test scores indicate that 19.5% of participants had objective olfactory impairment.

Conclusions and relevance: A significant proportion of COVID-19 cases have persistent chemosensory impairments at 3 to 7 months after their infection but the majority of those who had completely lost their olfactory, gustatory and trigeminal sensitivity have improved. Given the possible neurological underpinnings of this observation and the important number of individuals infected with SARS-CoV-2, further longitudinal studies are needed to better characterize this phenotype and to report eventual post-COVID-19 neurological sequelae.

Introduction:

Coronavirus disease-2019 (COVID-19) is an ongoing major public health challenge. Olfactory dysfunction (OD) is a specific symptom that may affect approximately 60% of patients suffering from COVID-19[1-3], and is now considered as a stronger indicator of COVID-19 than fever, cough and shortness of breath[4].

Investigation of the long-term effects of COVID-19 on chemosensory function is hindered by the recent onset of the pandemic and other challenges: First, many studies include a relatively small number of participants[5, 6] or participants with severe forms of COVID-19[7, 8]. Secondly, many studies include participants with an unclear diagnosis of COVID-19, and/or self-diagnosis [9, 10]. Lastly, while individuals with anosmia can usually evaluate their olfactory function with accuracy[11], this self-assessment is often challenging for individuals with intermediate forms of OD (e.g., hyposmia)[12].

OD can be quantitative or qualitative. Quantitative OD defines a reduction of olfactory sensitivity which can be either a complete (*anosmia*) or a partial (*hyposmia*) loss of olfactory function[13]. Qualitative OD describes an altered perception of olfactory stimuli, such as *parosmia*, the perception of qualitatively altered smells, or *phantosmia*, the perception of a smell in the absence of an objective odorant[13, 14]. Overall, the prevalence of OD in the general population is around 20% [15, 16], and all different forms of OD are associated with reduced quality of life and increased risk of depression and anxiety[17]. In addition to OD, COVID-19 also appears to affect other chemosensory functions, i.e. gustatory and trigeminal perception [9, 18].

To comprehensively understand long-term olfactory, gustatory, and trigeminal alterations after COVID-19, we analyzed questionnaire responses from a cohort of health care workers infected with SARS-CoV-2 during the first wave of the pandemic (February - June 2020). We

also developed a Chemosensory Perception Test (CPT), a formal test employing common household odorants and tastants, to enable accessible yet accurate self-evaluation of chemosensory functions.

Methods:

Study Design

This study was reviewed and approved by the research ethics board of the CHU de Québec – Université Laval (MP-20-2021-5228) and all protocols were reviewed by an independent Scientific Review Committee. All participants provided an online informed consent prior to participation. The study received funding from the Fonds de recherche du Québec-Santé. No compensation or incentive was offered for participation. Data were collected from August 11 to October 29, 2020. Up to four attempts were made to reach by email potential participants. At the time of data collection, participants were 3-7 months after the onset of COVID-19 symptoms.

Study Population:

Participants were recruited from a Quebec health care worker cohort who have had SARS-CoV-2 infection between 28/2/2020 and 14/6/2020. They were part of a study from the Institut National de Santé Publique du Québec and had agreed to be contacted for other research projects[19]. Inclusion criteria were (1) RT-PCR confirmed COVID-19 (2) above 18 years of age, (3) French or English speakers, (4) completed the online questionnaire, and (5) did not report of other respiratory diseases (bacterial or viral infection, or/and allergies with rhinorrhea) within 2 weeks prior to questionnaire completion or chronic sinusitis.

Online questionnaire:

All participants were asked to complete an online questionnaire which was adapted from the core questionnaire of the Global Consortium on Chemosensory Research[9].

Demographic information: In the first part of the questionnaire, demographic information was collected from all participants. Participants were then instructed to provide medical history and indicate the presence of specific COVID-19 symptoms (Figure S1).

Chemosensory self-assessment: Participants were asked to self-evaluate and report their olfactory, gustatory, and trigeminal sensitivity using a 10-point visual analog scale (VAS; Figure S1) for three timepoints: (1) before SARS-CoV-2 infection, (2) during SARS-CoV-2 infection and (3) at questionnaire completion. Further, information on the presence of parosmia or phantosmia following the infection[20] and alterations in the 5 tastes (sweet, salty, sour, bitter, umami) was collected.

Chemosensory Perception Test (CPT): Items commonly found in North American households were used to assess participants' olfactory and gustatory functions, as odor intensity is the best single predictor to classify individuals with normosmia[21]. Participants had to smell three substances (peanut butter, jam/jelly, and coffee) and rate odor intensity on a 10-point VAS (0: no smell at all; 10: very strong smell). We obtained olfactory scores by averaging these ratings. Pilot data on a total of 93 participants show these scores to be correlated with the established UPSIT ($r=0.377$; $P=0.004$) and to accurately detect OD when compared to the Sniffin' Sticks (cut-off score: 6; sensitivity: 0.765; specificity: 0.895; Supplement 3). Participants were asked to prepare saline and sweet water by dissolving respectively a teaspoon of salt or 3 teaspoons of sugar in a cup (250 mL) of lukewarm water. Then, they were asked to taste saline and sweet water and to rate taste intensities on a 10-point VAS. We obtained gustatory scores by averaging these ratings.

Statistical Analysis:

A Python script (Python 3.7.5, Python Software Foundation, https://www.python.org) was used to process raw questionnaire data and to calculate the number of participants reporting COVID-19 symptoms, chronic conditions and recent respiratory illnesses. Processed data were analyzed and visualized with SPSS 26.0 (Armonk, NY: IBM Corp), GraphPad Prism 8.3.1 (GraphPad Prism Software, San Diego, CA) and Raincloud plots[22].

Parametric (ANOVA) or non-parametric (Friedman) tests were chosen depending on whether normality assumption was fulfilled. To evaluate the effects of COVID-19 on *modality* (olfactory, gustatory, and trigeminal) and *time* (prior to, during and after COVID-19 infection), for *gender* (women, men), repeated measures (rm) ANOVA with age as a covariate were computed. To disentangle interactions, separate rmANOVA were carried out for individual modalities and timepoints with the same factors. Greenhouse-Geisser corrections were used for sphericity and Tukey's multiple comparisons test were used for post-hoc comparisons. Friedman's test was followed by Dunn's post-hoc test to correct for multiple comparisons. To assess the correlation between self-reported olfactory, gustatory, and trigeminal abilities and results of the CPT, Pearson correlation coefficient or Spearman's rank correlation coefficient was used. For all statistical tests, alpha was set at 0.05. All results are expressed as mean (SD) unless otherwise specified.

Results:

Characteristics of participants:

A total of 704 health care workers (593(84.2%) women, mean age of 42.0 (SD:11.7, range 18 – 70) years were included. The questionnaire was completed on average 4.8 (SD: 0.8, range 3-7) months after symptoms onset. COVID-19 symptoms reported by the 704 participants are listed in supplementary materials (Supplement 2).

Quantitative disorders:

Before COVID-19, average self-reported score was 9.0 (1.6), 9.2 (1.3) and 8.9 (1.9) of 10 for olfaction, gustation and trigeminal function, respectively. Among participants, 0.9%, 0.7% and 1.8% respectively reported an absence of olfaction, gustation and trigeminal function (score 0; Figure 2). During COVID-19, average self-reported score was 2.6 (3.6) for olfaction, 3.4 (3.6) for gustation, and 7.0 (3.0) for trigeminal sensitivity. In the 704 participants, 51.1%, 33.5% and 5.7% reported absence of olfaction, gustation and trigeminal function. At time of questionnaire completion, mean scores were 7.4 (2.5), 8.0 (2.2) and 8.5 (2.2) for olfaction, gustation and trigeminal function respectively and absence of chemical senses was reported respectively by 1.4%, 0.7% and 2.3%.

Compared to the baseline chemosensory functions before COVID-19, 572 (81.3%), 574 (81.5) and 338 (48.0%) reported lower olfactory, gustatory, and trigeminal sensitivity during COVID-19. Olfactory and gustatory dysfunction were present in similar proportions ($\chi^2(2, N=704) = 0.02$, $P=.891$) and were different to trigeminal (olfaction: $\chi^2(2, N=704) = 174.81$ $P<.001$; gustation: $\chi^2(2, N=704) = 174.56$ $P<.001$). Three to seven months after the infection, 366 (52.0%), 295 (41.9%), 164 (23.3%) reported lower olfactory, gustatory, and trigeminal

sensitivity compared to before COVID-19. These proportions were significantly different between all three chemosensory systems ($\chi^2(2, N=704) = 123.46$, $P<.001$).

Overall, there were significant effects of *modality* (F(2,1402)=42.83, $P<.001$, $\eta_p^2=0.058$; olfactory<gustatory<trigeminal; all $P<.001$), *time* (F(2,1402)=118.47, $P<.001$, $\eta_p^2=0.145$; during<after<before; all $P<.001$), and *gender* (F(1,701)=5.52, $P=0.019$, $\eta_p^2=0.008$; women<men) and significant interactions between these factors (*modality*time, modality*time*gender*; all $P<.001$) on chemosensory self-evaluation. To disentangle these interactions, we analyzed data separately per chemosensory modality and time points.

<u>Chemosensory modality</u>: With regards to <u>olfactory</u> function, significant main effects of *time* (F(2,1402)=165.07, $P<.001$ $\eta_p^2=0.191$; during<after<before; all $P<.001$; Figure 2A), *age* (F(1,701)=4.42, $P=.012$, $\eta_p^2=0.009$) and *gender* (F(1,701)=4.42, P=.036, $\eta_p^2=0.006$; women < men) were revealed. In addition, we observed significant interactions of *time*age* (F(2,1402)=23.39, $P<.001$, $\eta_p^2=0.032$) and *time*gender* (F(2, 1402)=21.69 , $P<0.001$, $\eta_p^2=0.030$).

With regards to <u>gustatory</u> function, we observed significant main effects of *time* (F(2,1402)=102.97, $P<.001$, $\eta_p^2=0.128$; during<after<before; all $P<.001$; Figure 2B) and *gender* (F(1, 701)=9.80, $P=.002$, $\eta_p^2=0.014$; women<men), but no effect of *age*. We also observed significant interactions of *time*age* (F(2, 1402))=5.97, $P=.005$, $\eta_p^2=0.008$) and *time*gender* (F(2, 1402))=20.02 , $P<.001$, $\eta_p^2=0.028$).

With regards to <u>trigeminal</u> function, we observed significant main effects of *time* (F(2,1402)=3.91, $P=.020$, $\eta_p^2=0.006$; during<after<before; all $P<.001$; Figure 2C), and age ((1,701)=5.08, $P=.025$, $\eta_p^2=0.007$) but no effect of *gender*. We also identified significant

interactions of *time*age* (F(2, 1402)=4.70, *P*=.016, η_p^2=0.007) and *time*gender* (F(2, 1402)=4.50, *P*=.019, η_p^2=0.006).

Time point: With regards to chemosensory function before infection, we observed a significant effect of *gender* (F(1,701)=8.52, *P*=.004, η_p^2=0.012; men < women), but not of *modality*, *age* nor interactions. During COVID-19, we observed a significant effects of *modality* (F(2, 1402)=96.714, *P*<.001, η_p^2=0.121; olfaction<gustation<trigeminal; all *P*<.001), *gender* (F(1, 701)=21.98, *P*<.001, η_p^2=0.030; women<men), and age (F(1, 701)=4.74, *P*=.030, η_p^2=0.007). Further, we found significant interactions *modality*age* (F(2, 1402)=24.185, *P*<.001, η_p^2=0.033) and *modality*gender* (F(2, 1402)=6.76, *P*=.002, η_p^2=0.010). Finally, after infection, we observed a significant effect of *modality* (F(2, 1402)=9.91, *P*<.001, η_p^2=0.014; olfaction<gustation<trigeminal; all *P*<.015), but not of *gender* or *age*, nor any interaction.

Compared to baseline (before infection), changes in chemosensory function were correlated for all modalities during infection (olfaction-gustation: ρ=0.69; gustation-trigeminal: ρ=0.43; olfaction-trigeminal: ρ=0.33; all *P*<.001, Figure 3 A-C) and after infection (olfaction-gustation: ρ=0.69; gustation-trigeminal: ρ=0.40; olfaction-trigeminal: ρ=0.36; all *P*<.001, Figure 3 D-F).

Qualitative disorders:

Among included participants, 78 (11.1%) reported parosmia, 73 (10.4%) experienced phantosmia and/or 82 (11.6%) had waxing and waning of olfaction following infection. In addition, 42 (6.0%) claimed that they experienced other forms of OD (hyposmia to specific substances, hyperosmia, parosmia only at high concentrations or slow identification times).

Furthermore, 335 (47.6%) participants reported changes to perception of sweet, 338 (48.0%) salty, 293 (41.6%) sour, 309 (43.9%) bitter and 281 (39.9%) umami. A total of 275 (39.1%) participants reported alterations in all 5 tastes.

Chemosensory Perception Test:

Among the 704 participants, 137 (19.5%) had a CPT score suggestive of OD. Mean CPT scores were lower for olfaction than gustation (7.84 (1.78) vs 8.42 (2.31); Z=8.193, *P*<.001). Neither *age* nor *gender* had an effect on CPT scores. CPT scores correlated with self-reported chemosensory abilities at testing time (olfaction: ρ=0.67; gustation: ρ=0.51; *P*<.001 for both).

Discussion:

This study reports chemosensory dysfunction 3 to 7 months following SARS-CoV-2 infection in a large cohort of RT-PCR-confirmed health care workers. In addition to confirming the now well-established detrimental effect of acute COVID-19 on all three chemosensory systems (olfactory, gustatory, trigeminal), our major findings are: (1) the detrimental effect of COVID-19 lasts beyond the acute phase after the infection, half of those affected indicated that olfactory function had not returned to the baseline levels 3 to 7 months later, while 20% of infected participants reported scores in a formal test that are consistent with the presentation of hyposmia/anosmia; (2) approximately 10% of the patients exhibit parosmia and/or phantosmia; (3) women are more heavily affected than men.

We observed chemosensory dysfunction in the acute phase of COVID-19, which was most pronounced for olfactory function, but less so for gustatory function and even less for trigeminal function. The proportion of participants describing OD and GD in the acute phase of COVID-19 in this study was comparable to earlier studies[23]. Nevertheless, on average 4.8 months after infection and thus well after the acute phase, approximately 50% and 40% of patients reported persistent alterations in olfactory and gustatory sensitivity, respectively; these numbers are higher than what has been reported[24, 25].

We found a moderate-to-strong correlation between self-reported olfactory and gustatory changes, which were stronger than with self-reported trigeminal changes. This could be due to similar pathophysiological alterations in the olfactory and gustatory systems and their differences from that of the trigeminal system. Knowing that the general population often mixes up retro-olfaction (perceiving odors from the substances in the mouth traveling posteriorly and rostrally to the olfactory epithelium) with taste, an alternative explanation would be a misunderstanding of

this nuance by participants despite the fact that specific definitions for each modality were given[26 27]. The latter hypothesis is more probable since the correlation between gustatory self-report and CPT gustatory scores using strict gustatory stimuli (salt, sugar) is lower than the correlation between olfactory self-report and CPT olfactory scores.

Moreover, approximately 10% reported parosmia and/or phantosmia following SARS-CoV-2 infection. These qualitative smell disorders usually involve unpleasant olfactory sensations (rotten eggs, sewage, smoke). While the exact pathomechanism of parosmia and phantosmia are still to be elucidated, parosmia is probably linked to altered peripheral input/central processing of olfactory stimuli[28]. Importantly, patients with postviral OD and parosmia exhibit better recovery rates following olfactory training than those without parosmia[29]. Follow-ups will determine to what extent parosmia predicts a better outcome.

Women's chemical senses were more affected than men by the infection. Women typically have better scores in olfactory testing than men [30]. In turn, women exhibit a higher prevalence and a longer persistence of postviral OD[31, 32], in line with our results. Gender differences could be explained by a multitude of neuroendocrine, social, and cognitive factors[31]. This suggests that the burden of COVID-19-related OD is more important for women than for men.

Different theories have been proposed to explain the persistence of OD in certain individuals, ranging from olfactory epithelium dysfunction to central nervous system infection [33-35]. Since cells of the olfactory epithelium possess the ability to regenerate, the re-establishment of olfactory function is possible in the context of postinfectious OD [36], as well as in COVID-19-related OD, where 75-85% of the affected individuals recovered olfactory function within 60 days [24, 37]. In addition to OD and GD, TD has also been reported in patients with COVID-19 [9, 18].

Our study indicates chemosensory dysfunction in 18.9% of participants as measured by the CPT 3 to 7 months after infection.

Persistent chemosensory dysfunctions may be a sign of chronic central nervous system alterations[38, 39], and there is now evidence that SARS-CoV-2 can infect olfactory sensory neurons in humans[40]. Other viruses, such as the Japanese encephalitis virus, Varicella-Zoster virus, measles virus, human immunodeficiency virus and CoVs, were shown to invade the CNS[41]. Febrile seizures, loss of consciousness, convulsions, ataxia, status epilepticus, encephalitis, myelitis, neuritis and extrapyramidal symptoms are among extra-pulmonary symptoms that have been described[42]. The persistence of postinfectious neurological symptoms may contribute to the development or aggravation of chronic neurological diseases such as Parkinson, multiple sclerosis, or psychiatric outcomes[41, 43-51]. These patients should be followed up to document the development of neurological sequalae.

Olfactory and other chemosensory dysfunctions may have detrimental effects. First, affected individuals can expose themselves to harmful substances such as smoke, gas or spoiled food[52, 53]. It may trigger dysfunctional nutritional patterns like increased salt and sugar consumption and anorexia[54, 55]. Individuals with OD also have higher rates of anxiety and depression[17, 56]. Moreover, a functioning olfactory system may be a necessity in some workplaces such as in healthcare, where staff are required to have the ability to detect and qualify the smell of urine, excrement, infected wounds or abnormal smells of breath[57]. Currently, there is no approved therapy for COVID-19-induced OD, although olfactory training has a significant effect on olfactory function according to studies on other viral infections[58-60]. Most importantly, long-term follow-up of these patients will be necessary to assess other signs of neurological damage.

Limitations

Given the cross-sectional design of the study, a recall bias is possible for all self-reported peri-SARS-CoV-2 infection values before or during the SARS-CoV-2 infection due to the 3-to-7-month gap. This study did not control for potential confounding factors like race and level of education. Finally, the CPT requires further validation for its gustatory and trigeminal components, and it relies on substances found in participants' homes, which may lead to variation in test results due to the differences in the brand, quality, or expiration date of substances and consequently, their ability to trigger equal sensorineural responses.

Conclusions:

Nearly two thirds of SARS-CoV-2 infected patients had chemosensory impairments during their infection and despite improvements, impairments persist in more than half of them 3 to 7 months after COVID-19. Quantitative and qualitative olfactory dysfunction as well as persisting gustatory and trigeminal deficits were common in the cohort presented in this study. Given the frequency of these problems and the possible neurological underpinnings of these observations, it will be critical to understand the underlying mechanisms of these chemosensory dysfunctions, their evolution, and possible therapeutic options.

Acknowledgments:

We thank Josiane Rivard for preparing the online questionnaire, Cécilia Tremblay, Émilie Aubry-Lafontaine and Frédérique Roy-Côté for data collection and the validation of the Chemosensory Perception Test, and all study participants and frontline health care workers facing the COVID-19 pandemic. This work was supported financially by Fonds de recherche du Québec – Santé (chercheur boursier junior 2 #283144 to JF). NB and JF had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is the recipient of a tier-2 Canada research Chair. All authors declare no conflict of interest.

References:

1. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA*. 2020;323 (20):2089-2090. doi:10.1001/jama.2020.6771 %J JAMA
2. Whitcroft KL, Hummel T. Olfactory Dysfunction in COVID-19: Diagnosis and Management. *JAMA*. 2020;323 (24):2512-2514. doi:10.1001/jama.2020.8391 %J JAMA
3. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. *ACS Chem Neurosci*. Oct 7 2020;11(19):2944-2961. doi:10.1021/acschemneuro.0c00460
4. Gerkin R, Ohla K, Veldhuizen M, Joseph P, Kelly C, Bakke A, et al. Recent Smell Loss Is the Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chemical Senses*. 02/01 2021;46
5. Le Bon S-D, Pisarski N, Verbeke J, Prunier L, Cavelier G, Thill M-P, et al. Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients. *Eur Arch Otorhinolaryngol*. 2020;doi:10.1007/s00405-020-06267-2
6. Hintschich CA, Wenzel JJ, Hummel T, Hankir MK, Kühnel T, Vielsmeier V, et al. Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients. *International forum of allergy & rhinology*. 2020;10(9):1105-1107. doi:10.1002/alr.22655
7. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;doi:10.1002/alr.22587
8. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics. *Otolaryngol Head Neck Surg*. 2020;doi:10.1177/0194599820929185
9. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More than smell. COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. *medRxiv*. 2020:2020.05.04.20090902. doi:10.1101/2020.05.04.20090902
10. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study. *Journal of Otolaryngology - Head & Neck Surgery*. 2020/05/04 2020;49(1):26. doi:10.1186/s40463-020-00423-8
11. Lötsch J, Hummel T. Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-Based Assessment of 6000 Patients. *Chem Senses*. Jul 17 2019;44(6):357-364. doi:10.1093/chemse/bjz029
12. Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory function. *Chem Senses*. Oct 2003;28(8):691-4. doi:10.1093/chemse/bjg061
13. Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. Position paper on olfactory dysfunction. *Rhinology*. Jan 31 2016;56(1):1-30. doi:10.4193/Rhin16.248
14. Sjölund S, Larsson M, Olofsson JK, Seubert J, Laukka EJ. Phantom Smells: Prevalence and Correlates in a Population-Based Sample of Older Adults. *Chemical senses*. 2017;42(4):309-318. doi:10.1093/chemse/bjx006
15. Yang J, Pinto JM. The Epidemiology of Olfactory Disorders. *Curr Otorhinolaryngol Rep*. 2016;4(2):130-141. doi:10.1007/s40136-016-0120-6
16. Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction. *Laryngoscope*. Oct 2004;114 (10):1764-9. doi:10.1097/00005537-200410000-00017
17. Croy I, Nordin S, Hummel T. Olfactory Disorders and Quality of Life—An Updated Review. *Chemical Senses*. 2014;39(3):185-194. doi:10.1093/chemse/bjt072
18. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*. 2020;107 (2):219-233. doi:10.1016/j.neuron.2020.06.032
19. Carazo SLD, Villeneuve J, Martin R, Deshaies P, Denis G, , Adib G, Tissot F, Dionne M, De Serres G Characterization and evolution of infection control practices among SARS-CoV-2 infected

healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring 2020. *Infect Contr Hospit Epidemiol*. in press 2021;
20. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of structured questions in parosmia assessment. *Laryngoscope*. Aug 2010;120 (8):1707-13. doi:10.1002/lary.20955
21. Parma V, Hannum ME, O'Leary M, Pellegrino R, Rawson NE, Reed DR, et al. SCENTinel 1.0: development of a rapid test to screen for smell loss. *Chem Senses*. Mar 27 2021;doi:10.1093/chemse/bjab012
22. Allen M, Poggiali D, Whitaker K, Marshall T, van Langen J, Kievit R. Raincloud plots: a multi-platform tool for robust data visualization [version 2; peer review: 2 approved]. *Wellcome Open Research*. 2021;4(63)doi:10.12688/wellcomeopenres.15191.2
23. Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, et al. Olfactory and gustatory dysfunction in COVID-19 patients: A meta-analysis study. *Physiol Rep*. Sep 2020;8(18): e14578. doi:10.14814/phy2.14578
24. Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. https://doi.org/10.1111/joim.13209. *Journal of Internal Medicine*. 2021/01/05 2021;n/a (n/a) doi:https://doi.org/10.1111/joim.13209
25. Capelli M, Gatti P. Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional recovery after eight months. *J Laryngol Otol*. 2021:1-5. doi:10.1017/S0022215121000670
26. Landis BN, Frasnelli J, Reden J, Lacroix JS, Hummel T. Differences Between Orthonasal and Retronasal Olfactory Functions in Patients With Loss of the Sense of Smell. *Archives of Otolaryngology–Head & Neck Surgery*. 2005;131 (11):977-981. doi:10.1001/archotol.131.11.977 %J Archives of Otolaryngology–Head & Neck Surgery
27. Malaty J, Malaty IA. Smell and taste disorders in primary care. *Am Fam Physician*. Dec 15 2013;88(12):852-9.
28. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia: An fMRI Study. *ORL J Otorhinolaryngol Relat Spec*. 2019;81(4):185-192. doi:10.1159/000500558
29. Liu DT, Sabha M, Damm M, Philpott C, Oleszkiewicz A, Hähner A, et al. Parosmia is Associated with Relevant Olfactory Recovery After Olfactory Training. *Laryngoscope*. Mar 2021;131 (3):618-623. doi:10.1002/lary.29277
30. Wang X, Zhang C, Xia X, Yang Y, Zhou C. Effect of gender on odor identification at different life stages: a meta-analysis. *Rhinology*. Oct 1 2019;57(5):322-330. doi:10.4193/Rhin19.005
31. Sorokowski P, Karwowski M, Misiak M, Marczak MK, Dziekan M, Hummel T, et al. Sex Differences in Human Olfaction: A Meta-Analysis. Systematic Review. 2019-February-13 2019;10 (242) doi:10.3389/fpsyg.2019.00242
32. Liu J, Pinto JM, Yang L, Li L, Sun J, Miao X, et al. Gender difference in Chinese adults with post-viral olfactory disorder: a hospital-based study. *Acta Otolaryngol*. Sep 2016;136 (9):976-81. doi:10.3109/00016489.2016.1172729
33. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*. 2020;doi:10.1177/1073858420956905
34. Solomon T. Neurological infection with SARS-CoV-2 — the story so far. *Nature Reviews Neurology*. 2021/02/01 2021;17(2):65-66. doi:10.1038/s41582-020-00453-w
35. Bilinska K, Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism. *ACS Chem Neurosci*. 2020;doi:10.1021/acschemneuro.0c00406
36. Cavazzana A, Larsson M, Münch M, Hähner A, Hummel T. Postinfectious olfactory loss: A retrospective study on 791 patients. *Laryngoscope*. Jan 2018;128 (1):10-15. doi:10.1002/lary.26606
37. Mullol J, Alobid I, Mariño-Sánchez F, Izquierdo-Domínguez A, Marin C, Klimek L, et al. The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. *Curr Allergy Asthma Rep*. 2020;20(10):61-61. doi:10.1007/s11882-020-00961-1

38. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain, Behavior, and Immunity*. 2020/03/30/ 2020;doi:https://doi.org/10.1016/j.bbi.2020.03.031
39. Gori A, Leone F, Loffredo L, Cinicola BL, Brindisi G, De Castro G, et al. COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. *Front Neurol*. 2020;11:956-956. doi:10.3389/fneur.2020.00956
40. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*. Nov 30 2020;doi:10.1038/s41593-020-00758-5
41. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. *Cell Host Microbe*. Apr 17 2013;13(4):379-93. doi:10.1016/j.chom.2013.03.010
42. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. *Front Cell Neurosci*. 2018;12:386. doi:10.3389/fncel.2018.00386
43. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J Virol*. Oct 2000;74(19):8913-21. doi:10.1128/jvi.74.19.8913-8921.2000
44. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. *Lancet Neurol*. Oct 2020;19(10):804-805. doi:10.1016/s1474-4422 (20)30305-7
45. Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia M, Cereda PM. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. *New Microbiol*. Apr 1997;20(2):105-14.
46. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. *Mov Disord*. 1992;7(2):153-8. doi:10.1002/mds.870070210
47. Johnson-Lussenburg CM, Zheng Q. Coronavirus and multiple sclerosis: results of a case/control longitudinal serological study. *Adv Exp Med Biol*. 1987;218:421-9. doi:10.1007/978-1-4684-1280-2_51
48. Morris JA. Clinical viral infections and multiple sclerosis. *Lancet*. Aug 3 1985;2 (8449):273. doi:10.1016/s0140-6736(85)90318-6
49. Murray RS, Brown B, Brian D, Cabirac GF. Detection of coronavirus RNA and antigen in multiple sclerosis brain. *Ann Neurol*. May 1992;31(5):525-33. doi:10.1002/ana.410310511
50. Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. *Virology*. Nov 1992;191 (1):502-5. doi:10.1016/0042-6822 (92)90220-j
51. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. Apr 1 2021;doi:10.1016/s2215-0366 (21)00084-5
52. Schiffman SS. Smell and Taste. In: Birren JE, ed. *Encyclopedia of Gerontology (Second Edition)*. Elsevier; 2007:515-525.
53. Gonzales GM, Cook MJ. CHAPTER 13 - DISORDERS OF SMELL AND TASTE. In: Schapira AHV, Byrne E, DiMauro S, et al, eds. *Neurology and Clinical Neuroscience*. Mosby; 2007:171-177.
54. Aschenbrenner K, Hummel C, Teszmer K, Krone F, Ishimaru T, Seo HS, et al. The influence of olfactory loss on dietary behaviors. *Laryngoscope*. Jan 2008;118 (1):135-44. doi:10.1097/MLG.0b013e318155a4b9
55. Mattes R, Cowart B, Schiavo M, Arnold C, Garrison B, Kare M, et al. Dietary evaluation of patients with smell and/or taste disorders. *The American journal of clinical nutrition*. 03/01 1990;51:233-40. doi:10.1093/ajcn/51.2.233
56. Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The Association Between Olfaction and Depression: A Systematic Review. *Chem Senses*. Jul 2016;41(6):479-86. doi:10.1093/chemse/bjw061
57. Kelly M. Scent of a patient: an underestimated role in clinical practice? *Br J Gen Pract*. 2012;62 (600):378-378. doi:10.3399/bjgp12X652481
58. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta-analysis. *Rhinology*. Mar 1 2017;55(1):17-26. doi:10.4193/Rhin16.195

59. Doty RL. Treatments for smell and taste disorders: A critical review. *Handb Clin Neurol*. 2019;164:455-479. doi:10.1016/b978-0-444-63855-7.00025-3
60. Damm M, Pikart LK, Reimann H, Burkert S, Göktas Ö, Haxel B, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. *Laryngoscope*. Apr 2014;124 (4):826-31. doi:10.1002/lary.24340
61. Rumeau C, Nguyen DT, Jankowski R. How to assess olfactory performance with the Sniffin' Sticks test®. *European Annals of Otorhinolaryngology, Head and Neck Diseases*. 2016/06/01/ 2016;133 (3):203-206. doi:https://doi.org/10.1016/j.anorl.2015.08.004
62. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav*. Mar 1984;32(3):489-502. doi:10.1016/0031-9384 (84)90269-5

List of tables:

Table 1. Self-reported chemosensory alterations by age group and gender during and 3 to 7 months following COVID-19 (n=704)

		During acute COVID-19			3-7 months after COVID-19		
		Olfaction	Gustation	Trigeminal	Olfaction	Gustation	Trigeminal
Age	Gender	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
18-29	M (N= 11)	9 (81.8)	9 (81.8)	4 (36.4)	6 (54.5)	5 (45.5)	3 (27.3)
	F (N=115)	106 (92.2)	106 (92.2)	54 (47.0)	68 (59.1)	55 (47.8)	16 (13.9)
30-39	M (N=26)	23 (88.5)	21 (80.8)	12 (46.2)	13 (50.0)	7 (26.9)	4 (15.4)
	F (N=153)	133 (86.9)	129 (84.3)	77 (50.3)	83 (54.2)	63 (41.2)	37 (24.2)
40-49	M (N=33)	23 (69.7)	23 (69.7)	13 (39.4)	12 (36.4)	9 (27.3)	5 (15.2)
	F (N=165)	142 (85.5)	137 (83.0)	83 (50.3)	97 (58.8)	77 (46.7)	42 (25.5)
50-59	M (N=28)	13 (46.4)	14 (50.0)	9 (32.1)	7 (25.0)	7 (25.0)	4 (14.3)
	F (N=128)	100 (78.1)	102 (79.7)	66 (51.6)	62 (48.4)	57 (44.5)	39 (30.5)
60+	M (N=13)	5 (38.5)	6 (46.2)	5 (38.5)	2 (15.4)	1 (7.7)	3 (23.1)
	F (N=32)	19 (59.4)	27 (84.4)	15 (46.9)	16 (50.0)	14 (43.8)	11 (34.4
	Total (N=704)	**572 (81.3)**	**574 (81.5)**	**338 (48.0)**	**366 (52.0)**	**295 (41.9)**	**164 (23.2)**

List of figures:

Figure 1. Flowchart of participant inclusion/exclusion procedures. Flowchart of the study design. INSPQ: Institut national de santé publique.



Figure 2. Self-reported scores for the chemosensory modalities before, during and after COVID-19 infection (n=704). Raincloud plot representing self-reported scores for olfaction, gustation, and trigeminal function before, during and after COVID-19. Ratings from individual participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, self-reported scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19 and have not fully returned to baseline values 5 months after COVID-19.



Figure 3. Correlations between alterations in chemosensory modalities (n=704). Red squares, correlations between alterations in olfaction, gustation, and trigeminal functions during COVID-19. Grey hexagons, correlations between alterations in olfaction, gustation, and trigeminal functions after COVID-19. Darker colors indicate higher occurrence.